List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7626512/publications.pdf Version: 2024-02-01



ΜΑΡΙΑΝ ΕΥΟΠΝΟ

#	Article	IF	CITATIONS
1	Coordinate roles for collagen VI and biglycan in regulating tendon collagen fibril structure and function. Matrix Biology Plus, 2022, 13, 100099.	3.5	7
2	Type <scp>VI</scp> Collagen Regulates Endochondral Ossification in the Temporomandibular Joint. JBMR Plus, 2022, 6, e10617.	2.7	5
3	Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy. Breast Cancer Research, 2021, 23, 51.	5.0	29
4	OPC-Fc treatment partially rescues low bone mass phenotype in mature Bgn/Fmod deficient mice but is deleterious to the young mouse skeleton. Journal of Structural Biology, 2020, 212, 107627.	2.8	5
5	Wisp1 is a circulating factor that stimulates proliferation of adult mouse and human beta cells. Nature Communications, 2020, 11, 5982.	12.8	23
6	Collagen VIα2 chain deficiency causes trabecular bone loss by potentially promoting osteoclast differentiation through enhanced TNFα signaling. Scientific Reports, 2020, 10, 13749.	3.3	13
7	Biglycan in the Skeleton. Journal of Histochemistry and Cytochemistry, 2020, 68, 747-762.	2.5	30
8	WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. Oncolmmunology, 2019, 8, e1581545.	4.6	28
9	CCN4/WISP1 controls cutaneous wound healing by modulating proliferation, migration and ECM expression in dermal fibroblasts via î±5î²1 and TNFî±. Matrix Biology, 2018, 68-69, 533-546.	3.6	54
10	Cell-surface phosphatidylserine regulates osteoclast precursor fusion. Journal of Biological Chemistry, 2018, 293, 254-270.	3.4	67
11	Isolation, production, and analysis of small leucine-rich proteoglycans in bone. Methods in Cell Biology, 2018, 143, 281-296.	1.1	13
12	Extracellular Matrix Mediates BMP-2 in a Model of Temporomandibular Joint Osteoarthritis. Cells Tissues Organs, 2017, 204, 84-92.	2.3	14
13	Small leucine rich proteoglycans, a novel link to osteoclastogenesis. Scientific Reports, 2017, 7, 12627.	3.3	45
14	Analysis of CCN4 Function in Osteogenic and Osteoclastic Cells Using Gain and Loss of Function Approaches. Methods in Molecular Biology, 2017, 1489, 347-359.	0.9	0
15	Systems Nutrigenomics Reveals Brain Gene Networks Linking Metabolic and Brain Disorders. EBioMedicine, 2016, 7, 157-166.	6.1	59
16	Skeletal biology: Where matrix meets mineral. Matrix Biology, 2016, 52-54, 1-6.	3.6	21
17	Biglycan potentially regulates angiogenesis during fracture repair by altering expression and function of endostatin. Matrix Biology, 2016, 52-54, 141-150.	3.6	39
18	CCN4/WISP-1 positively regulates chondrogenesis by controlling TGF-Î ² 3 function. Bone, 2016, 83, 162-170.	2.9	28

#	Article	IF	CITATIONS
19	Fluocinolone Acetonide Is a Potent Synergistic Factor of TGF·l̂²3–Associated Chondrogenesis of Bone Marrow–Derived Mesenchymal Stem Cells for Articular Surface Regeneration. Journal of Bone and Mineral Research, 2015, 30, 1585-1596.	2.8	29
20	Mice Deficient in <i>AKAP13</i> (<i>BRX</i>) Are Osteoporotic and Have Impaired Osteogenesis. Journal of Bone and Mineral Research, 2015, 30, 1887-1895.	2.8	15
21	Tendon Functional Extracellular Matrix. Journal of Orthopaedic Research, 2015, 33, 793-799.	2.3	171
22	The Small Leucine-Rich Proteoglycan BGN Accumulates in CADASIL and Binds to NOTCH3. Translational Stroke Research, 2015, 6, 148-155.	4.2	36
23	WNT1-induced Secreted Protein-1 (WISP1), a Novel Regulator of Bone Turnover and Wnt Signaling. Journal of Biological Chemistry, 2015, 290, 14004-14018.	3.4	79
24	Bone Matrix Proteoglycans in Skeletal Function. , 2014, , 85-95.		0
25	Biglycan modulates angiogenesis and bone formation during fracture healing. Matrix Biology, 2014, 35, 223-231.	3.6	76
26	Interclass small leucine-rich repeat proteoglycan interactions regulate collagen fibrillogenesis and corneal stromal assembly. Matrix Biology, 2014, 35, 103-111.	3.6	76
27	Nanofiber scaffold gradients for interfacial tissue engineering. Journal of Biomaterials Applications, 2013, 27, 695-705.	2.4	58
28	WISP1/CCN4: A Potential Target for Inhibiting Prostate Cancer Growth and Spread to Bone. PLoS ONE, 2013, 8, e71709.	2.5	64
29	The Biology of Small Leucine-rich Proteoglycans in Bone Pathophysiology. Journal of Biological Chemistry, 2012, 287, 33926-33933.	3.4	130
30	Biglycan Is an Extracellular MuSK Binding Protein Important for Synapse Stability. Journal of Neuroscience, 2012, 32, 2324-2334.	3.6	59
31	Biglycan. Journal of Histochemistry and Cytochemistry, 2012, 60, 963-975.	2.5	196
32	Biglycan: a promising new therapeutic for neuromuscular and musculoskeletal diseases. Current Opinion in Genetics and Development, 2012, 22, 398-400.	3.3	18
33	Freeform fabricated scaffolds with roughened struts that enhance both stem cell proliferation and differentiation by controlling cell shape. Biomaterials, 2012, 33, 4022-4030.	11.4	121
34	Small Leucine-Rich Proteoglycans. , 2011, , 197-231.		23
35	Dentin structure composition and mineralization. Frontiers in Bioscience - Elite, 2011, E3, 711-735.	1.8	504
36	Fabricating Gradient Hydrogel Scaffolds for 3D Cell Culture. Combinatorial Chemistry and High Throughput Screening, 2011, 14, 227-236.	1.1	24

#	Article	IF	CITATIONS
37	The determination of stem cell fate by 3D scaffold structures through the control of cell shape. Biomaterials, 2011, 32, 9188-9196.	11.4	264
38	Modulus-driven differentiation of marrow stromal cells in 3D scaffolds that is independent of myosin-based cytoskeletal tension. Biomaterials, 2011, 32, 2256-2264.	11.4	113
39	WISP-1/CCN4 regulates osteogenesis by enhancing BMP-2 activity. Journal of Bone and Mineral Research, 2011, 26, 193-208.	2.8	120
40	Combinatorial screening of osteoblast response to 3D calcium phosphate/poly(ε-caprolactone) scaffolds using gradients and arrays. Biomaterials, 2011, 32, 1361-1369.	11.4	55
41	The Proteoglycan Biglycan Enhances Antigen-Specific T Cell Activation Potentially via MyD88 and TRIF Pathways and Triggers Autoimmune Perimyocarditis. Journal of Immunology, 2011, 187, 6217-6226.	0.8	46
42	Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17022-17027.	7.1	144
43	Differential Effects of Fibromodulin Deficiency on Mouse Mandibular Bones and Teeth: A Micro-CT Time Course Study. Cells Tissues Organs, 2011, 194, 205-210.	2.3	18
44	Deficiency of Biglycan Causes Cardiac Fibroblasts to Differentiate into a Myofibroblast Phenotype. Journal of Biological Chemistry, 2011, 286, 17365-17375.	3.4	60
45	The effect of 3D hydrogel scaffold modulus on osteoblast differentiation and mineralization revealed by combinatorial screening. Biomaterials, 2010, 31, 5051-5062.	11.4	265
46	Biglycan and Fibromodulin Have Essential Roles in Regulating Chondrogenesis and Extracellular Matrix Turnover in Temporomandibular Joint Osteoarthritis. American Journal of Pathology, 2010, 176, 812-826.	3.8	97
47	The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. Journal of Clinical Investigation, 2010, 120, 4251-4272.	8.2	177
48	Genetic Evidence for the Coordinated Regulation of Collagen Fibrillogenesis in the Cornea by Decorin and Biglycan. Journal of Biological Chemistry, 2009, 284, 8888-8897.	3.4	192
49	Fibromodulin-Deficient Mice Reveal Dual Functions for Fibromodulin in Regulating Dental Tissue and Alveolar Bone Formation. Cells Tissues Organs, 2009, 189, 198-202.	2.3	22
50	The Potential Functional Interaction of Biglycan and WISP-1 in Controlling Differentiation and Proliferation of Osteogenic Cells. Cells Tissues Organs, 2009, 189, 153-157.	2.3	41
51	Regeneration of bone and periodontal ligament induced by recombinant amelogenin after periodontitis. Journal of Cellular and Molecular Medicine, 2009, 13, 1110-1124.	3.6	37
52	Biglycan, a Danger Signal That Activates the NLRP3 Inflammasome via Toll-like and P2X Receptors. Journal of Biological Chemistry, 2009, 284, 24035-24048.	3.4	407
53	Genetic evidence for key roles of decorin and biglycan in dentin mineralization. Matrix Biology, 2009, 28, 129-136.	3.6	54
54	Absence of Biglycan Accelerates the Degenerative Process in Mouse Intervertebral Disc. Spine, 2009, 34, E911-E917.	2.0	40

4

#	Article	IF	CITATIONS
55	TGFâ€Î²1 and WISPâ€1/CCNâ€4 can regulate each other's activity to cooperatively control osteoblast function. Journal of Cellular Biochemistry, 2008, 104, 1865-1878.	2.6	52
56	Hedgehog Signaling in Mature Osteoblasts Regulates Bone Formation and Resorption by Controlling PTHrP and RANKL Expression. Developmental Cell, 2008, 14, 674-688.	7.0	170
57	Impact on Bone of an Estrogen Receptor-α Gene Loss of Function Mutation. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3088-3096.	3.6	74
58	Pharmacologic Stem Cell Based Intervention as a New Approach to Osteoporosis Treatment in Rodents. PLoS ONE, 2008, 3, e2615.	2.5	155
59	Biglycan Deficiency Causes Spontaneous Aortic Dissection and Rupture in Mice. Circulation, 2007, 115, 2731-2738.	1.6	126
60	Impaired posterior frontal sutural fusion in the biglycan/decorin double deficient mice. Bone, 2007, 40, 861-866.	2.9	24
61	Exercise-induced changes in the cortical bone of growing mice are bone- and gender-specific. Bone, 2007, 40, 1120-1127.	2.9	128
62	Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nature Medicine, 2007, 13, 1219-1227.	30.7	1,211
63	Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. Bone, 2006, 38, 778-786.	2.9	80
64	The mechanical phenotype of biglycan-deficient mice is bone- and gender-specific. Bone, 2006, 39, 106-116.	2.9	44
65	Animal models of osteoarthritis: lessons learned while seeking the â€~Holy Grail'. Current Opinion in Rheumatology, 2006, 18, 537-547.	4.3	113
66	Biglycan binds to α- and γ-sarcoglycan and regulates their expression during development. Journal of Cellular Physiology, 2006, 209, 439-447.	4.1	54
67	Fibromodulin-deficient Mice Display Impaired Collagen Fibrillogenesis in Predentin as Well as Altered Dentin Mineralization and Enamel Formation. Journal of Histochemistry and Cytochemistry, 2006, 54, 525-537.	2.5	71
68	Extracellular Matrix Proteoglycans Control the Fate of Bone Marrow Stromal Cells. Journal of Biological Chemistry, 2005, 280, 30481-30489.	3.4	220
69	Mice Deficient in Biglycan and Fibromodulin as a Model for Temporomandibular Joint Osteoarthritis. Cells Tissues Organs, 2005, 181, 136-143.	2.3	44
70	Variation in Mineral Properties in Normal and Mutant Bones and Teeth. Cells Tissues Organs, 2005, 181, 144-153.	2.3	50
71	The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. Journal of Clinical Investigation, 2005, 115, 2223-2233.	8.2	718
72	Dissection of the sets of genes that control the behavior of biglycan-deficient pre-osteoblasts using oligonucleotide microarrays. Bone, 2005, 37, 192-203.	2.9	14

#	Article	IF	CITATIONS
73	Mouse models of osteoarthritis provide new research tools. Trends in Pharmacological Sciences, 2005, 26, 333-335.	8.7	18
74	A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. Journal of Clinical Investigation, 2004, 114, 1704-1713.	8.2	221
75	Regulation, Regulatory Activities, and Function of Biglycan. Critical Reviews in Eukaryotic Gene Expression, 2004, 14, 301-316.	0.9	46
76	Decorin Deficiency Leads to Impaired Angiogenesis in Injured Mouse Cornea. Journal of Vascular Research, 2004, 41, 499-508.	1.4	106
77	The small leucineâ€rich proteoglycan biglycan modulates BMPâ€4â€induced osteoblast differentiation. FASEB Journal, 2004, 18, 948-958.	0.5	255
78	Transient up-regulation of biglycan during skeletal muscle regeneration: delayed fiber growth along with decorin increase in biglycan-deficient mice. Developmental Biology, 2004, 268, 358-371.	2.0	92
79	Regulation of Fibrillin-1 by Biglycan and Decorin Is Important for Tissue Preservation in the Kidney During Pressure-Induced Injury. American Journal of Pathology, 2004, 165, 383-396.	3.8	55
80	Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet, The, 2004, 364, 149-155.	13.7	2,920
81	Biglycan Deficiency Interferes With Ovariectomy-Induced Bone Loss. Journal of Bone and Mineral Research, 2003, 18, 2152-2158.	2.8	46
82	Biglycan-Deficient Mice Have Delayed Osteogenesis after Marrow Ablation. Calcified Tissue International, 2003, 72, 577-582.	3.1	37
83	Bone matrix proteins: their function, regulation, and relationship to osteoporosis. Osteoporosis International, 2003, 14, 35-42.	3.1	192
84	Expression of transcription factors and matrix genes in response to serum stimulus in vascular smooth muscle cells. European Journal of Cell Biology, 2003, 82, 119-129.	3.6	10
85	ΔNp63α functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. Oncogene, 2003, 22, 3635-3644.	5.9	135
86	Exercise Can Reverse the Phenotype of Biglycan Deficient Mice. , 2003, , .		1
87	Abnormal collagen fibrils in tendons of biglycan/fibromodulinâ€deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB Journal, 2002, 16, 673-680.	0.5	305
88	Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology, 2002, 12, 107R-116R.	2.5	378
89	Gene Expression Profile of Human Bone Marrow Stromal Cells: High-Throughput Expressed Sequence Tag Sequencing Analysis. Genomics, 2002, 79, 7-17.	2.9	51
90	Transcriptional regulation restricting bone sialoprotein gene expression to both hypertrophic chondrocytes and osteoblasts. Journal of Cellular Biochemistry, 2002, 87, 458-469.	2.6	8

#	Article	IF	CITATIONS
91	Age-Related Osteoporosis in Biglycan-Deficient Mice Is Related to Defects in Bone Marrow Stromal Cells. Journal of Bone and Mineral Research, 2002, 17, 331-340.	2.8	134
92	Phenotypic Effects of Biglycan Deficiency Are Linked to Collagen Fibril Abnormalities, Are Synergized by Decorin Deficiency, and Mimic Ehlers-Danlos-Like Changes in Bone and Other Connective Tissues. Journal of Bone and Mineral Research, 2002, 17, 1180-1189.	2.8	392
93	Biglycan knockout mice: New models for musculoskeletal diseases. Glycoconjugate Journal, 2002, 19, 257-262.	2.7	151
94	The human tuftelin gene: cloning and characterization. Gene, 2001, 279, 181-196.	2.2	42
95	Differential display of human marrow stromal cells reveals unique mRNA expression patterns in response to dexamethasone. Journal of Cellular Biochemistry, 2000, 76, 231-243.	2.6	60
96	A TGF-?-inducible cell adhesion molecule, ?ig-h3, is downregulated in melorheostosis and involved in osteogenesis. , 2000, 77, 169-178.		108
97	Bone Sialoprotein Mediates Human Endothelial Cell Attachment and Migration and Promotes Angiogenesis. Circulation Research, 2000, 86, 885-891.	4.5	113
98	Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack. Journal of Biological Chemistry, 2000, 275, 16666-16672.	3.4	188
99	Double FYVE-containing protein 1 (DFCP1): isolation, cloning and characterization of a novel FYVE finger protein from a human bone marrow cDNA library. Gene, 2000, 255, 195-203.	2.2	24
100	Efficient Gene Transfer into Normal Human Skeletal Cells Using Recombinant Adenovirus and Conjugated Adenovirus-DNA Complexes. Calcified Tissue International, 1999, 64, 45-49.	3.1	8
101	Paracrine or virus-mediated induction of decorin expression by endothelial cells contributes to tube formation and prevention of apoptosis in collagen lattices. European Journal of Cell Biology, 1999, 78, 44-55.	3.6	141
102	Estrogen receptors in bone. Current Opinion in Orthopaedics, 1999, 10, 361-366.	0.3	0
103	Immortalization and Characterization of Bone Marrow Stromal Fibroblasts from a Patient with a Loss of Function Mutation in the Estrogen Receptor-α Gene. Journal of Bone and Mineral Research, 1998, 13, 598-608.	2.8	15
104	Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nature Genetics, 1998, 20, 78-82.	21.4	543
105	Receptor tyrosine kinase expression in human bone marrow stromal cells. , 1998, 177, 426-438.		88
106	Tuftelin – aspects of protein and gene structure. European Journal of Oral Sciences, 1998, 106, 315-323.	1.5	28
107	PHOG, a candidate gene for involvement in the short stature of Turner syndrome. Human Molecular Genetics, 1997, 6, 1341-1347.	2.9	255
108	Functional Characterization of the Human Biglycan 5′-Flanking DNA and Binding of the Transcription Factor c-Krox. Journal of Bone and Mineral Research, 1997, 12, 2050-2060.	2.8	28

#	Article	IF	CITATIONS
109	The Human Bone Sialoprotein Gene Contains an NF-E1/YY1 Cis-Acting Sequence with Putative Regulatory Activity. Calcified Tissue International, 1997, 60, 276-282.	3.1	9
110	The X-chromosomal human biglycan gene BGN is subject to X inactivation but is transcribed like an X-Y homologous gene. Human Genetics, 1995, 96, 44-52.	3.8	57
111	Regulated Expression of Osteopontin in Human Trophoblasts. Annals of the New York Academy of Sciences, 1995, 760, 346-349.	3.8	10
112	Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthopaedica, 1995, 66, 61-65.	1.4	366
113	Cloning and sequence analysis of bovine bone sialoprotein cDNA: Conservation of acidic domains, tyrosine sulfation consensus repeats, and RGD cell attachment domain. Journal of Bone and Mineral Research, 1994, 9, 417-421.	2.8	12
114	Human Decorin Gene: Intron-Exon Junctions and Chromosomal Localization. Genomics, 1993, 15, 161-168.	2.9	42
115	The Human Bone Sialoprotein Gene (IBSP): Genomic Localization and Characterization. Genomics, 1993, 17, 408-415.	2.9	73
116	Partial characterization of a novel â€~GGA'factor which binds to the osteonectin promoter in bovine bone cells. Gene, 1993, 130, 225-232.	2.2	15
117	Journal of Bone and Mineral Research. Journal of Bone and Mineral Research, 1993, 8, S483-S487.	2.8	94
118	MOLECULAR AND CELLULAR BIOLOGY OF THE MAJOR NONCOLLAGENOUS PROTEINS IN BONE. , 1993, , 191-2:	34.	27
119	Structure, Expression, and Regulation of the Major Noncollagenous Matrix Proteins of Bone. Clinical Orthopaedics and Related Research, 1992, &NA, 275???294.	1.5	169
120	Renal tubular epithelial cells express osteonectin in vivo and in vitro. Kidney International, 1992, 41, 56-64.	5.2	14
121	Bone matrix mRNA expression in differentiating fetal bovine osteoblasts. Journal of Bone and Mineral Research, 1992, 7, 743-754.	2.8	133
122	The cDNA cloning and RNA distribution of bovine osteopontin. Gene, 1991, 108, 237-243.	2.2	60
123	Structure and expression of the bovine amelogenin gene. Biochemistry, 1991, 30, 1075-1079.	2.5	87
124	Identification of the leucine-rich amelogenin peptide (LRAP) as the translation product of an alternatively spliced transcript. Biochemical and Biophysical Research Communications, 1991, 174, 1306-1312.	2.1	104
125	Expression of bone sialoprotein (BSP) in developing human tissues. Calcified Tissue International, 1991, 49, 421-426.	3.1	385
126	Diverse forms of stress results in changes in cellular levels of osteonectin/SPARC without altering mRNA levels in osteoligament cells. Calcified Tissue International, 1991, 49, 58-62.	3.1	15

#	Article	IF	CITATIONS
127	Expression of the osteonectin gene potentially controlled by multiple Cis- and trans-acting factors in cultured bone cells. Journal of Bone and Mineral Research, 1991, 6, 1127-1136.	2.8	17
128	Changes in osteonectin distribution and levels are associated with mineralization of the chicken tibial growth cartilage. Calcified Tissue International, 1990, 47, 51-61.	3.1	82
129	Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues Journal of Histochemistry and Cytochemistry, 1990, 38, 1549-1563.	2.5	626
130	cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics, 1990, 7, 491-502.	2.9	344
131	Interaction of Osteonectin and Type I Collagen in Bone Cells. Annals of the New York Academy of Sciences, 1990, 580, 526-528.	3.8	3
132	Structure and Expression of Osteonectin Mrna in Human Tissue. Connective Tissue Research, 1990, 24, 17-28.	2.3	56
133	Localization of PGI (biglycan, BGN) and PGII (decorin, DCN, PG-40) genes on human chromosomes Xq13-qter and 12q, respectively. Genomics, 1990, 6, 219-225.	2.9	64
134	Thrombospondin is an osteoblast-derived component of mineralized extracellular matrix Journal of Cell Biology, 1989, 108, 719-727.	5.2	123
135	Opposing Influences of Glucocorticoid and Retinoic Acid on Transcriptional Control in Preosteoblasts. Molecular Endocrinology, 1989, 3, 2079-2085.	3.7	65
136	Localization of osteonectin expression in human fetal skeletal tissues byin situ hybridization. Calcified Tissue International, 1989, 45, 146-152.	3.1	55
137	Synthetic Peptide Antisera: Their Production and Use in the Cloning of Matrix Proteins. Connective Tissue Research, 1989, 21, 43-50.	2.3	38
138	Isolation of the osteonectin gene: evidence that a variable region of the osteonectin molecule is encoded within one exon. Biochemistry, 1988, 27, 1483-1489.	2.5	40
139	Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro Journal of Cell Biology, 1987, 105, 457-463.	5.2	560
140	Bone glycoproteins. Methods in Enzymology, 1987, 145, 269-289.	1.0	10
141	Osteontctin mRNA: distribution in normal and transformed cells. Nucleic Acids Research, 1986, 14, 4483-4497.	14.5	111
142	Characterization of bone PG II cDNA and its relationship to PG II mRNA from other connective tissues. Nucleic Acids Research, 1986, 14, 9861-9876.	14.5	43
143	Isolation and partial characterization of genomic clones coding for a human proalpha.1(II) collagen chain and demonstration of restriction fragment length polymorphism at the 3' end of the gene. Biochemistry, 1985, 24, 6343-6348.	2.5	20
144	Isolation of cDNA and genomic DNA clones encoding type II collagen. Nucleic Acids Research, 1984, 12, 4207-4228.	14.5	79